Fexlamose

N/A

Report date: 2025/05/29 20:00:08
NME

Base Information

Drug NameFexlamose
Drug Alias Namemucolytic agent (Charite Universitaetsmedizin Berlin/Univ College Dublin/Trinity College Dublin/Univ California San Francisco/Berlin Inst of Health)6,6'-dithiotrehaloseMUC-031AER-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMucolytic agentsAngiotensin-converting enzyme 2 inhibitors
TargetsAngiotensin-converting enzyme 2
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveLung DiseasesCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTrinity College DublinUniversity College DublinUniversity Of California San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoAer Therapeutics IncTrinity College Dublin +[6] 
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveLung DiseasesCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A